TY - JOUR T1 - High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma JF - Anticancer Research JO - Anticancer Res SP - 6731 LP - 6738 VL - 35 IS - 12 AU - ZARAH GLAD ZIMLING AU - ERIC SANTONI-RUGIU AU - CECILIA BECH AU - JENS BENN SØRENSEN Y1 - 2015/12/01 UR - http://ar.iiarjournals.org/content/35/12/6731.abstract N2 - Background/Aim: A possible predictive impact of ribonucleotide-reductase subunit-1 (RRM1) on vinorelbine efficacy in non-small cell lung cancer (NSCLC) has been previously reported. The present study aimed to further explore this finding in malignant pleural mesothelioma (MPM). Materials and Methods: Seventy-one patients with MPM receiving first-line chemotherapy with cisplatin-vinorelbine (CiV group, n=54) or carboplatin-pemetrexed (CaP group, n=17) were included. Formalin-fixed paraffin-embedded tumor specimens were analyzed by immunohistochemistry (IHC) for RRM1 expression using an H-score. Results: In 66 patients eligible for IHC, the H-score was ≥upper quartile in 21 (RRM1-positive) and <upper quartile (RRM1-negative) in 45 cases. The long-term (2-year) survival rate for patients with RRM1-negative MPM in the CiV-treated group was significantly superior to that for patients with RRM1-positive MPM (47% versus 13%, p=0.002). No difference occurred in the CaP-treated group. Conclusion: Our findings suggest a possible role of RRM1 in predicting efficacy of cisplatin–vinorelbine in MPM, supporting previous findings in NSCLC. ER -